Literature DB >> 25582234

Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?

James N George1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25582234      PMCID： PMC4295634          DOI： 10.1111/trf.12885

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  8 in total

1.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

2.  Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Nan Wu; Jia Liu; Shangbin Yang; Eric T Kellett; Spero R Cataland; Hong Li; Haifeng M Wu
Journal:  Transfusion       Date:  2014-06-23       Impact factor: 3.157

3.  Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).

Authors:  Neil Shah; Cynthia Rutherford; Karen Matevosyan; Yu-Min Shen; Ravi Sarode
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

Review 4.  Syndromes of thrombotic microangiopathy.

Authors:  James N George; Carla M Nester
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

5.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

7.  Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura.

Authors:  Rahel Froehlich-Zahnd; James N George; Sara K Vesely; Deirdra R Terrell; Khatira Aboulfatova; Jing-Fei Dong; Brenda M Luken; Jan Voorberg; Ulrich Budde; Irmela Sulzer; Bernhard Lämmle; Johanna A Kremer Hovinga
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

8.  Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.

Authors:  James N George; Qiaofang Chen; Cassie C Deford; Zayd Al-Nouri
Journal:  J Clin Apher       Date:  2012-08-28       Impact factor: 2.821
  8 in total
  4 in total

1.  Von Willebrand factor regulates complement on endothelial cells.

Authors:  Damien G Noone; Magdalena Riedl; Fred G Pluthero; Mackenzie L Bowman; M Kathryn Liszewski; Lily Lu; Yi Quan; Steve Balgobin; Reinhard Schneppenheim; Sonja Schneppenheim; Ulrich Budde; Paula James; John P Atkinson; Nades Palaniyar; Walter H A Kahr; Christoph Licht
Journal:  Kidney Int       Date:  2016-05-25       Impact factor: 10.612

2.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood Adv       Date:  2017-04-06

3.  Acute kidney injuries induced by thrombotic microangiopathy following severe hemorrhage in puerperants: a case series and literature review.

Authors:  Xu Wang; Chun-Yan Liu; Yue Yang; Gu-Ming Zou; Li Zhuo; Su-Hui Han; Wen-Ge Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients.

Authors:  Giulia Berti de Marinis; Stefano Novello; Silvia Ferrari; Isabella Barzon; Irene Cortella; Maria Antonietta Businaro; Fabrizio Fabris; Anna Maria Lombardi
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.